Early Parkinson’s Disease diagnosis and treatment decisions
Key Questions
What subtle symptoms often lead to delayed Parkinson’s diagnosis?
Early signs such as stiffness, handwriting changes, loss of smell, and anxiety are frequently misattributed to aging or other conditions, delaying accurate Parkinson’s diagnosis.
How are digital biomarkers being used in early Parkinson’s trials?
Herantis Pharma is partnering with Indivi to incorporate digital biomarker technology that can sensitively detect motor and cognitive changes in early Parkinson’s disease trials.
What progress has been made with stem cell therapy for Parkinson’s?
Investigational dopaminergic stem cell replacement therapies have shown safety and preliminary motor improvements in early-phase clinical trials for Parkinson’s disease.
When should patients consider starting MAO-B inhibitors or Sinemet?
Clinicians often discuss MAO-B inhibitors like Azilect or initiating Sinemet based on symptom severity, patient lifestyle preferences, and individual disease progression.
How can lifestyle changes support early Parkinson’s management?
Patient-driven approaches including regular exercise, stress reduction, and maintaining hobbies are recommended alongside medication to help manage early Parkinson’s symptoms.
Subtle symptoms often misattributed. MAO-B inhibitors, Sinemet, lifestyle. New: Herantis HER-096 Indivi digital biomarkers; dopaminergic stem cell replacement Phase 1 safety + motor gains.